Navigation Links
Latest Study on Stem Cell Therapy Shows Promising Signs of Recovery for Stroke Patients and Support for StemGenex® Stem Cell Therapy
Date:9/3/2014

La Jolla, CA (PRWEB) September 03, 2014

A new study, published on Aug. 8th, 2014 in Stem Cells Translational Medicine, has shown the positive effect stem cell therapy has had on a group of patients only 6 months after their treatment. Researchers observed significant improvements in disease-related complications in each of the 5 patients included in the study. Post-treatment brain scans of each patient revealed that stroke-related damage was reduced over time. Further, at six-month follow-ups patients demonstrated improvements in standard measures of stroke-related disability and impairment.

Researchers are being cautiously optimistic when considering these results. Similar improvements are often seen in stroke patients as part of the normal recovery process and state that more thorough studies will need to be completed. Nonetheless, the findings are absolutely astounding as the five patients included in this study suffered severe strokes. Four out of five of the patients had the most serious type of stroke. Normally only 4% of these patients survive and are able to live independently after six months of a stroke occurrence.

Clinical studies for stem cell treatment are currently being offered by StemGenex® to patients diagnosed with Stroke and other degenerative neurological diseases. Innovation is truly a driving force for StemGenex. “Stroke Patients who receive stem cell treatment through StemGenex receive multiple therapeutic modalities they simply cannot find elsewhere under one roof,” said Jeremiah McDole, Director of Scientific Research and Development at StemGenex. Offering targeted therapies that deliver stem cells past the blood brain barrier is essential to providing effective treatment for patients with neurological disorders.

StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative neurological diseases including Multiple Sclerosis, Parkinson’s Alzheimer’s disease, and others. Rita Alexander, founder of StemGenex and the company’s first stem cell patient, insists that all patients be treated like they are one of our loved ones. “Hope, compassion, and the relentless pursuit for an end to these diseases are the primary focus.”

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com

Read the full story at http://www.prweb.com/releases/2014/09/prweb12139660.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Jellyfish inspires latest ocean-powered robot
2. San Diego Medical Director Wins Two Book Awards For Latest Medical Thriller
3. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
4. Van Andel Institute Research Symposium Showcases Latest Developments In Parkinsons Research
5. Can Cannabidiol (CBD) Fight Metastatic Cancer? According to the latest research the answer is yes.
6. Karmanos Cancer Center first in Midwest to offer latest Molecular Breast Imaging
7. Cieri Media Announces New Science Series 'Bright Ideas' Focusing on Latest Inventions
8. New CfPIE Website Highlights Life Science Training Options for the Latest FDA Guidances and Standards
9. Latest Environmental Research Featured at ScienceAlerts.com
10. PolyScience to Exhibit Its Latest Liquid Temperature Control Solutions at Pittcon 2013
11. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):